SUSAN HILSENBECK to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications SUSAN HILSENBECK has written about Drug Screening Assays, Antitumor.
Connection Strength
0.070
-
Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: comparison with taxol and conventional antineoplastic agents. Eur J Cancer. 1993; 29A(14):2009-14.
Score: 0.025
-
MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol. 2000 Jul-Aug; 22(4):306-14.
Score: 0.010
-
Significant activity of a novel cytotoxic agent, LY295501, against a wide range of tumors in the human tumor cloning system. Anticancer Drugs. 1999 Mar; 10(3):303-7.
Score: 0.010
-
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs. 1994 Apr; 5(2):202-6.
Score: 0.007
-
The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth. Cancer Chemother Pharmacol. 1994; 34(2):89-95.
Score: 0.007
-
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units. Anticancer Drugs. 1992 Apr; 3(2):143-6.
Score: 0.006
-
Preclinical activity of ilmofosine against human tumor colony forming units in vitro. Anticancer Drugs. 1992 Feb; 3(1):43-6.
Score: 0.006